Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.39 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15468273 | 0.92 | DDB1 (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468176 | 0.91 | DDB1 (0.52) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468173 | 0.86 | DDB1 (0.49) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468184 | 0.85 | DDB1 (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468178 | 0.83 | DDB1 (0.53) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468186 | 0.82 | DDB1 (0.49) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468278 | 0.82 | DDB1 (0.64) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468175 | 0.82 | DDB1 (0.52) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468174 | 0.81 | DDB1 (0.49) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15468179 | 0.80 | DDB1 (0.52) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140314752-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885DDB1 820/4885IKZF3 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.